Drug Trial Radar · NCT05480657
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
Last checked: Nov 19, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 30, 2022
Primary completion
Aug 2024
Study completion Aug 2028
Sponsor
- Lead sponsor
- Eledon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
Conditions
- Brittle Type 1 Diabetes Mellitus
Interventions
AT-1501 IV InfusionBiological
Investigational study drug
Isolated cadaveric islet cellsBiological
Infusion of human cadaveric islet cells into the portal vein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)Time frame: Accessed from date of transplant through Day 364 post final transplant for approximately 2 years
- Efficacy - Insulin independenceTime frame: Date of transplant through Day 364 post- final transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.